As depicted in Fig
Furthermore, although tirzepatide did lead to marked improvements in AHI, there was residual OSA in many participants, emphasizing the need to treat both OSA and obesity rather than either one alone
Divide your prescribed milligram dose by the concentration to get the volume in milliliters, then multiply by 100 to convert to insulin syringe units: Dose (mg) / Concentration (mg/mL) = Volume (mL) Volume (mL) x 100 = Units on syringe So for a 7.5mg dose at 10mg/mL: 7.5 / 10 = 0.75mL = 75 units
Most people are on their maintenance dose, the body has fully adapted, and the remaining experience is primarily the therapeutic benefit (reduced appetite, ongoing weight loss or maintenance) without the adjustment symptoms
Think of it as preventative medicine, with some anti-aging perks baked in: Grab a fork, and dig in
This happened with other unapproved compounded drugs in the past